Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia in Dialysis Subjects With Chronic Kidney Disease

• Status: Recruiting
• Trial end date: 2021-11-30

Summary

This is a randomized, open-label, multi-center study in dialysis CKD subjects to evaluate the efficacy and relative safety of different dosing regimens of roxadustat over a 36-week treatment period.

There are three study periods:

• Screening Period (up to 4 weeks)

• Treatment Period (36 weeks)

Part 1: Correction/Conversion Period (weeks 1-20)

Part 2: Hemoglobin (Hb) Maintenance Period (weeks 21-36)

• Follow-up Period (4 weeks)

• Phase: Phase 4

Details

• Lead Sponsor: FibroGen